Abstracts tagged "Comorbidity"

Abstract Number: 2243 • 2018 ACR/ARHP Annual Meeting
Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults
Angelo Gaffo¹, Elizabeth J. Rahn², Tanja Dudenbostel¹, Amy S. Mudano¹, Peng Li³, David T. Redden³, Stephanie Biggers¹, Phillip J. Foster², Paul M. Muntner⁴, Suzanne Oparil⁵, David A. Calhoun⁵ and Kenneth Saag¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Serum urate (sUA) has been associated with blood pressure in most but not all studies. This study aims to test whether there are sex…
Abstract Number: 2320 • 2018 ACR/ARHP Annual Meeting
Multimorbidity Is Associated with Hip Fractures in Both Women and Men and across Different Races
Shreyasee Amin¹, Elizabeth J. Atkinson² and Sundeep Khosla², ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Multimorbidity, the coexistence of 2 or more chronic conditions, is associated with increased disability and poor functional status, and may serve as an important…
Abstract Number: 2507 • 2018 ACR/ARHP Annual Meeting
Healthcare Resource Utilization in Patients with Secondary Sjögren’s Syndrome Associated with RA Compared with Patients with RA in an Insured Population
Evo Alemao¹, Aarti Rao², Chidananda Samal² and Robert Wong¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India
Background/Purpose: Secondary Sjögren’s syndrome (sSS) is a rheumatic disease that may coexist with RA. Joint disease is more severe in patients (pts) with RA with…
Abstract Number: 325 • 2018 ACR/ARHP Annual Meeting
A Comparison of RADAI5 and RAPID3 Disease Measures
Ryan Jessee, Amanda M. Eudy and Megan E. B. Clowse, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: Treat to target has been shown to improve outcomes in multiple rheumatology diseases although relies on accurate disease measures. Our academic clinic routinely measures…
Abstract Number: 2719 • 2018 ACR/ARHP Annual Meeting
Tracking the Risk of Infections in ANCA-Associated Vasculitis: Results from a Scottish Matched-Cohort Study
Shifa Sarica¹, Neeraj Dhaun², Jan Sznajd³, John Harvie³, Nicola Joss³, John McLaren⁴, Lucy McGeoch⁵, Nicole Amft⁶, Vinod Kumar⁷, Angharad Marks¹, Corri Black¹ and Neil Basu¹, ¹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom, ²University/British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, ³Department of Rheumatology, Raigmore Hospital, Inverness, United Kingdom, ⁴Fife Rheumatic Diseases Unit, Whyteman's Brae Hospital, Kirkcaldy, United Kingdom, ⁵Center for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁶Department of Rheumatology, Western General Hospital, Edinburgh, United Kingdom, ⁷Rheumatology Department, Ninewells Hospital, Dundee, United Kingdom
Background/Purpose: Evaluation of infection risk in ANCA-associated vasculitis (AAV) has been limited to small, selected populations and/or serious episodes. In this large study, we aimed…
Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Christopher Banse¹, Nicolas Chrin², Pascal Rottenberg³, Sophie Pouplin⁴, thierry Lequerre⁵ and Olivier Vittecoq³, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, ³INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁴Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France
Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
Abstract Number: 1004 • 2017 ACR/ARHP Annual Meeting
Arthritis Impact at the State and County Level — United States, 2015
Kamil E. Barbour¹, Suson Moss², Janet Croft², Jennifer M. Hootman³, Louise Murphy⁴, Kristina Theis², Yan Wang², Hua Lu², Teresa J. Brady¹ and Charles G. Helmick², ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³Centers for Disease Control and Prevention, Kennesaw, GA, ⁴Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Arthritis, a leading cause of disability, affects 54.4 million US adults. By knowing the state and county level arthritis impact, state-level public health professionals…
Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting
Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Patrick R. Wood¹, Evan Manning², Joshua Baker³, Grant Cannon⁴, Lisa Davis⁵, Bryant R. England⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Div of Rheumatology, Denver Health, Denver, CO, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁷Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance. Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…
Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Atul A. Deodhar¹, Kevin Winthrop², Benjamin Chan², Sarah A. R. Siegel², Lisa Pisenti³, Jeffrey Stark³, Robert Y. Suruki⁴, Rhonda L. Bohn⁴, Huifeng Yun⁵, Lang Chen⁵ and Jeffrey R. Curtis⁵, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³UCB Pharma, Smyrna, GA, ⁴UCB Pharma, Raleigh, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…
Abstract Number: 1902 • 2017 ACR/ARHP Annual Meeting
A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Jon T. Giles¹, Cheilonda Johnson², Elana J. Bernstein³, Erika Darrah⁴, Felipe Andrade⁵ and Sonye K. Danoff⁶, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Columbia University, New York, NY, ⁴Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The pathogenesis and prediction of RA-associated interstitial lung disease (ILD), an extra-articular manifestation with high morbidity and mortality, is poorly understood. We explored the…
Abstract Number: 2309 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Cynthia K. Manos^1,2, Rui Xiao³, Timothy G. Brandon¹, Alexis Ogdie⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, PA, ³Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis. It…
Abstract Number: 2388 • 2017 ACR/ARHP Annual Meeting
Women and Men with Rheumatoid Arthritis Present with Different Risks for Glucocorticoid-Related Comorbidities
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Thorsten Eidner³, Stefan Kleinert⁴, Wolfgang Ochs⁵ and Angela Zink⁶, ¹Epidemiology Unit, German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Univeris, Berlin, Germany, ³Rheumatology/ Osteology, Friedrich-Schiller-University Jena, University Clinic, Jena, Germany, ⁴Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, ⁶Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: Osteoporosis, diabetes, hypertension and cardiovascular diseases are the most threatening glucocorticoid (GC)-related comorbidities in rheumatoid arthritis (RA), both from the patients and rheumatologists perspective1.…
Abstract Number: 1231 • 2016 ACR/ARHP Annual Meeting
Impact of Comorbidity on Health-Related Quality of Life and Healthcare Expenditure in Patients with Rheumatoid Arthritis
Eric Nyarko¹ and J An², ¹College of Pharmacy, Western University of Health Sciences, Pomona, CA, ²Western University of Health Sciences, Pomona, CA
Background/Purpose: Rheumatoid Arthritis (RA) is known to be associated with an increased risk of comorbidity, premature mortality, and disability. We investigated the effect of comorbidity…
Abstract Number: 1235 • 2016 ACR/ARHP Annual Meeting
Healthcare Utilization and Multimorbidities Among Adult Patients with Juvenile Idiopathic Arthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler⁷, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁶Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Active juvenile idiopathic arthritis (JIA) is commonly associated with high healthcare costs in children. The disabling consequences and multimorbidities often manifest, however, in adulthood.…
Abstract Number: 1480 • 2016 ACR/ARHP Annual Meeting
Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients
Samina A. Turk¹, Dirkjan van Schaardenburg^1,2, Willem F. Lems^1,3 and Mike T. Nurmohamed^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality. This cardiovascular risk is mainly determined by the lipid profile, which may change…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].